Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).

Journal: Journal of robotic surgery
PMID:

Abstract

To investigate the incidence and risk factors of inguinal hernia (IH) after robot-assisted radical prostatectomy (RARP) using a multicentric database. The present study used a multicentric database (the MSUG94) containing data on 3,195 Japanese patients undergoing RARP between 2012 and 2021. Surgical procedures utilized for IH prevention were as follows: isolation of the vas deferens, transection of the vas deferens, isolation of the spermatic vessels, and separation of the peritoneum from the internal inguinal ring. The primary and secondary endpoints were IH-free survival and any association between post-RARP IH and clinical covariates. The prophylactic effect of the above procedures were also assessed. IH prevention was attempted in 1,465 (46.4%) patients at five of the nine hospitals. During follow-up (median 24 months), post-RARP IH developed in 243 patients. The post-RARP IH-free survival rates at years 1, 2, and 3 were 94.3%, 91.7%, and 90.5%, respectively. Old age (hazard ratio [HR] 1.037; 95% confidence interval [CI] 1.014-1.061; p = 0.001), low BMI (HR 0.904; 95% CI 0.863-0.946: p < 0.001), and low hospital volume (HR 1.385; 95% CI 1.003-1.902; p = 0.048) were independently associated with IH development. None of the procedures for IH prevention were associated with IH development. Our findings may represent the current, real-world status of post-RARP IH in Japan. The prophylactic effects of the surgical procedures for IH prevention should be further investigated in well-designed, prospective studies to optimize the surgical technique.

Authors

  • Masahiro Toide
    Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Shin Ebara
  • Tomoyuki Tatenuma
    Department of Urology, Kanagawa Cancer Center.
  • Yoshinori Ikehata
    Department of Urology, University of Toyama, Toyama, Japan.
  • Akinori Nakayama
    Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
  • Makoto Kawase
    Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.
  • Takeshi Sasaki
    Department of Next-Generation Pathology Information Networking, Faculty of Medicine, The University of Tokyo.
  • Tatsuaki Yoneda
    Department of Urology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
  • Kazushige Sakaguchi
    Department of Urology, Toranomon Hospital, Tokyo, Japan.
  • Jun Teishima
    Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Kazuhide Makiyama
    Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Hiroshi Kitamura
    Department of Urology, University of Toyama, Toyama, Japan.
  • Kazutaka Saito
    Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
  • Takuya Koie
    Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.
  • Takahiro Inoue
    Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
  • Shinji Urakami
    Department of Urology, Toranomon Hospital, Tokyo, Japan.
  • Fumitaka Koga
    Department of Urology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. f-koga@cick.jp.